Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
Total Operating Expenses: $14.4 million for the three months ended September 30, 2024. Research and Development Expenses: $8.1 million for the three months ended September 30, 2024. General and Administrative Expenses: $6.3 million for the three months ended September 30, 2024. Debt Financing: Secured $30 million from Avenue Capital Group. Warning! GuruFocus has detected 2 Warning Signs with OCGN. Release Date: November 08, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Ocugen Inc ( NASDAQ:OCGN ) received approval from Health Canada to initiate the OCU400 Phase 3 clinical trial, expanding their reach to a broader patient population. The company secured $30 million in debt financing from Avenue Capital Group, extending their financial runway into the first quarter of 2026. OCU400 received FDA approval for an Expanded Access Program (EAP) for adult patients with retinitis pigmentosa, validating the safety data
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.MarketBeat
- Ocugen (OCGN) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Ocugen Provides Business Update with Third Quarter 2024 Financial ResultsGlobeNewswire
- Ocugen Secures $30 Million in Debt FundingGlobeNewswire
OCGN
Earnings
- 8/8/24 - Beat
OCGN
Sec Filings
- 11/15/24 - Form 3
- 11/15/24 - Form 8-K
- 11/14/24 - Form 10-Q
- OCGN's page on the SEC website